Skip to main content

Pharvaris N.V.

corporate_fare Company Profile

Pharvaris N.V.

PHVS·NASDAQ·Life Sciences·CIK 0001830487

Pharvaris N.V. is a late-stage biopharmaceutical company that develops and commercializes therapies for rare diseases with unmet needs, specifically focusing on angioedema and other diseases mediated by bradykinin. The company's primary product is deucrictibant, a small molecule bradykinin B2-receptor antagonist. Deucrictibant is being developed to treat attacks caused by bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH). This therapy is currently in Phase 3 trials for the treatment of HAE attacks and also in Phase 3 trials for the prophylaxis (prevention) of HAE attacks. Pharvaris N.V. is developing both an extended-release tablet and an immediate-release capsule formulation of deucrictibant. The company was incorporated in 2015 and its headquarters are located in Zug, Switzerland.

Pharvaris N.V. (NASDAQ:PHVS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for PHVS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Deucrictibant Phase 3 Data Shows Rapid, Sustained Efficacy for Angioedema, Meeting All Endpoints
  • Pharvaris Outlines 2026 Strategic Priorities, Confirms NDA Filing and Key Phase 3 Data Timelines

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$175.7M
Diluted EPS
-$2.97
Op. Cash Flow
-$137.07M
Free Cash Flow
-$137.24M
Operating Income
-$173.71M
Cash & Equivalents
$291.68M
Debt / Equity
0.00×
Shares Outstanding
65.21M sh
Source: 20-F · filed 2026-04-02 · accession 0001830487-26-000013

Insider Transactions

PHVS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$31.28
52-week range · as of 2026-11-12 $22.41 – $43.25
Market cap
$2.21B
Volume
464K (0.8× avg)
3-mo avg 572K
Live data · 2026-11-22 12:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PHVS - Filings & News (Page 2)

PHVS
Mar 02, 2026, 6:50 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $28.39
Real-time Price: $31.28 info
Change: +$2.89 (+10%) info
Market Cap: $2.214B info
PHVS
Jan 12, 2026, 6:51 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $25.89
Real-time Price: $31.28 info
Change: +$5.39 (+21%) info
Market Cap: $2.214B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets